Literature DB >> 16923813

Caffeine targets TOR complex I and provides evidence for a regulatory link between the FRB and kinase domains of Tor1p.

Aaron Reinke1, Jenny C-Y Chen, Sofia Aronova, Ted Powers.   

Abstract

The target of rapamycin (TOR) kinase is an important regulator of growth in eukaryotic cells. In budding yeast, Tor1p and Tor2p function as part of two distinct protein complexes, TORC1 and TORC2, where TORC1 is specifically inhibited by the antibiotic rapamycin. Significant insight into TORC1 function has been obtained using rapamycin as a specific small molecule inhibitor of TOR activity. Here we show that caffeine acts as a distinct and novel small molecule inhibitor of TORC1: (i) deleting components specific to TORC1 but not TORC2 renders cells hypersensitive to caffeine; (ii) rapamycin and caffeine display remarkably similar effects on global gene expression; and (iii) mutations were isolated in Tor1p, a component specific to TORC1, that confers significant caffeine resistance both in vivo and in vitro. Strongest resistance requires two simultaneous mutations in TOR1, the first at either one of two highly conserved positions within the FRB (rapamycin binding) domain and a second at a highly conserved position within the ATP binding pocket of the kinase domain. Biochemical and genetic analyses of these mutant forms of Tor1p support a model wherein functional interactions between the FRB and kinase domains, as well as between the FRB domain and the TORC1 component Kog1p, regulate TOR activity as well as contribute to the mechanism of caffeine resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16923813     DOI: 10.1074/jbc.M603107200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  95 in total

Review 1.  Mechanisms regulating the protein kinases of Saccharomyces cerevisiae.

Authors:  Eric M Rubenstein; Martin C Schmidt
Journal:  Eukaryot Cell       Date:  2007-03-02

2.  TOR1 and TOR2 have distinct locations in live cells.

Authors:  Thomas W Sturgill; Adiel Cohen; Melanie Diefenbacher; Mark Trautwein; Dietmar E Martin; Michael N Hall
Journal:  Eukaryot Cell       Date:  2008-08-22

3.  H3K36 Methylation Regulates Nutrient Stress Response in Saccharomyces cerevisiae by Enforcing Transcriptional Fidelity.

Authors:  Stephen L McDaniel; Austin J Hepperla; Jie Huang; Raghuvar Dronamraju; Alexander T Adams; Vidyadhar G Kulkarni; Ian J Davis; Brian D Strahl
Journal:  Cell Rep       Date:  2017-06-13       Impact factor: 9.423

4.  Rapamycin and mTOR kinase inhibitors.

Authors:  Lisa M Ballou; Richard Z Lin
Journal:  J Chem Biol       Date:  2008-05-15

5.  A system to identify inhibitors of mTOR signaling using high-resolution growth analysis in Saccharomyces cerevisiae.

Authors:  Mitchell B Lee; Daniel T Carr; Michael G Kiflezghi; Yan Ting Zhao; Deborah B Kim; Socheata Thon; Margarete D Moore; Mary Ann K Li; Matt Kaeberlein
Journal:  Geroscience       Date:  2017-07-13       Impact factor: 7.713

6.  Mutations in critical domains confer the human mTOR gene strong tumorigenicity.

Authors:  Avaniyapuram Kannan Murugan; Ali Alzahrani; Mingzhao Xing
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157

7.  mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels.

Authors:  Kaveh M Goudarzi; Monica Nistér; Mikael S Lindström
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

Review 8.  TOR-dependent control of autophagy: biting the hand that feeds.

Authors:  Thomas P Neufeld
Journal:  Curr Opin Cell Biol       Date:  2009-12-16       Impact factor: 8.382

9.  A phenotypic profile of the Candida albicans regulatory network.

Authors:  Oliver R Homann; Jeanselle Dea; Suzanne M Noble; Alexander D Johnson
Journal:  PLoS Genet       Date:  2009-12-24       Impact factor: 5.917

10.  Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCalpha.

Authors:  Thomas W Sturgill; Michael N Hall
Journal:  ACS Chem Biol       Date:  2009-12-18       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.